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Abstract
Considerable evidence has accumulated suggesting that cancer has genetic origin, based on the
development of genomic alterations, such as deletions, mutations, and/or methylations in critical
genes for homeostasis of cellular functions, including cell survival, DNA replication and cell cycle
control. Mechanism controlling the precise timing and sequence of cell cycle events as well as
checkpoints insuring fidelity of those events are key targets that when disrupted could result in
tumorigenesis. Mitosis is the process by which a cell duplicates its genetic information (DNA), in
order to generate two, identical, daughter cells. In addition each daughter cell must receive one
centrosome and the appropriate complements of cytoplasm and organelles. This process is
conventionally divided in to five distinct stages: prophase, prometaphase, metaphase, anaphase and
telophase that correspond to a different morphology of the cell. The entry into mitosis (M) is under
the control of the cyclin dependent kinase Cdk1. During G2, the kinases Wee1 and Myt1
phosphorylate Cdk1 at T14/Y15 residues, rendering it inactive. The transition from G2 to M is
promoted by the activation of Cdk1 via dephosphorylation by the Cdk1 phosphatase Cdc25C.
Activated Cdk1 complexes translocate into the nucleus during prophase where phosphorylate
numerous substrates in order to enhance their activation as the cells progresses trough prophase,
prometaphase, and metaphase.
Recently we identified a new player: FEZ1/LZTS1 that contributes to the fine-tuning of the
molecular events that determine progression through mitosis, and here will review its role in
cancer development and in M phase regulation.
Background
Frequent loss of heterozygosity (LOH) at specific chromo-
somal regions in tumors implies the presence of tumor
suppressor genes. One of these regions, located at the
short arm of chromosome 8 (8p21.3–22) has been
pointed out as frequently lost in different human malig-
nancies as well as implicated in tumor progression. Inves-
tigation of this region, in primary esophageal cancer, has
allowed the identification of the human FEZ1/LZTS1
(Leucine-Zipper Tumor Suppressor 1) gene at chromo-
some 8p22 [1]. LZTS1 gene show in non-cancerous cells a
6.8 kb mRNA including a 1.7 kb open reading frame
(ORF), spanning exons 1–3, which encodes a 596-aa pro-
tein of 67 kDa [1]. Homology search of databases showed
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1) and it has 32% identity to the DNA binding domain of
a cAmp-responsive activating transcription factor, Atf-5,
although Lzts1 lacks the DNA recognition sub-domain
usually found upstream of a Leucine-zipper motif in tran-
scription factor. Moreover, searches for motifs and com-
positional analyses inside the Lzts1 protein sequence
revealed the presence of multiple potential phosphoryla-
tion sites for different kinases (Fig. 1), such as PKA, CDC2
and PKC. The product of the LZTS1 gene is the founding
member of a three member family proteins, all of which
harbor a Leucine zipper Fez domain [2,3]. Interestingly
protein alignment of the three members (Lzts1, Lzts2 and
Lzts3) showed significant sequences similarity, particu-
larly in the C-terminal potential Leucine zipper regions.
Although recently has been reported [4] that the nuclear
export sequence identified in Lzts2 is not conserved in
both the Lzts1 and the Lzts3 proteins, suggesting a poten-
tial role for Lzts2 in the regulation of nuclear and cyto-
plasmic trafficking, which may reveal a different function
for this family member.
Expression pattern of LZTS1 in Primary Tumors and in 
Cancer Cell lines
Immunohistochemical studies of primary tumors indi-
cated that Lzts1 protein expression in cancer cells is absent
or markedly reduced in many different cancers compared
with non-cancerous tissue [5-8]. Our previous studies
showed that the expression of Lzts1 protein was undetec-
table or markedly reduced in 44% (39/88 cases) of pri-
mary gastric cancer with significant correlation to diffuse
histotype (P < 0.001) [5], in 62% (37/60 cases) of primary
transitional cell carcinoma of bladder with significant cor-
relation to histopathological tumor grade (P < 0.005) [6],
and in 64% (7/11 cases) of Bellini duct carcinoma [7].
Other studies showed that Lzts1 protein was lost or
reduced in 68% (70/103 cases) of lung cancer with differ-
ent histotypes, with a positive association with the tumor
grade [8]. Overall, ~60% of different primary tumors
showed loss or reduction of Lzts1 protein expression in
cancer cells. Western blot and RT-PCR analyses in differ-
ent cancer derived cell lines showed similar result [5-10],
arguing that loss or reduction of LZTS1 is a frequent event
in cancer development and progression. In addition
LZTS1 is also mutated and/or deleted in several cancer
types. We analyzed LZTS1 ORF (exon 1–3) in a total of
220 cancers, from 72 primary esophageal cancers, 18
esophageal cancer cell lines, 24 primary prostate cancers,
3 prostate cancer cell lines, 39 primary breast cancers, 25
breast cancer cell lines, 8 primary ovarian cancers, 4 leuke-
mic cell lines, 1 cervical cancer cell line [1] and 26 primary
gastric cancers [5], regardless of the presence or absence of
LZTS1 expression. We found four point mutations in two
primary esophageal cancers, in a prostate cancer cell line,
and in a primary gastric carcinoma. In a primary esopha-
geal tumor, alteration of TCC to CCC at codon 29 resulted
in the substitution of Ser-29 with Pro-29, which is a pre-
dicted cAMP-dependent kinase phosphorylation site. In
another primary esophageal cancer, alteration of AAG/Lys
to GAG/Glu at codon 119 was found. Our LOH study
Structural Functional Domains of Lzts1 proteinFigure 1
Structural Functional Domains of Lzts1 protein. Putative phosphorylation motifs of various kinases cAMP-dependent 
protein kinase A (PKA, in blue), protein kinase C (PKC, in green), cGMP-dependent kinase (PKG, in prugna), casein kinases I 
and II (CK1 and CK2, in green and in red, respectively), CDC2 kinase (CDC2, in orange), tyrosine kinase (TyrKin, in magenta). 
The Leucine residues of Leucine zipper motifs are indicated by the gray color.Page 2 of 5
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D8S261 marker. Thus, these tumor cells retained the
mutated LZTS1 allele and lost the normal LZTS1 allele by
point mutation. The third point mutation was the change
of CAG/Gln to TAG/Stop at codon 501 in a prostate can-
cer cell line, PC3, which resulted in coding of a putative
166-aa protein lacking the C terminus. The fourth muta-
tion was a somatic missense mutation (CAC/His to CGC/
Arg at LZTS1 codon 17) of one allele in a diffuse-type gas-
tric carcinoma.
We identified, by RT-PCR, several internally truncated
transcripts in esophageal cancer, prostate cancer,
melanoma, and hematological malignancies (Table 1).
The transcript from two independent esophageal cancers
showed a frameshift within the ORF, which resulted in
coding a short 76-aa protein [1]. We analyzed the nucle-
otide sequences around "breakpoints" of the deleted
cDNAs and compared them to sequences from the full-
length cDNA. The results showed that all of the acceptor
sites contain the intronic AG flanking the exons, suggest-
ing that the deleted transcripts in several tumors may be
produced by alternative splicing.
More recently a detailed DNA sequence analysis of LZTS1
was performed in a screening panel consisting of sporadic
and hereditary prostate cancer (HPC) cases and unaf-
fected controls. Twenty-four single nucleotide polymor-
phism (SNP), 15 of which were novel, were identified in
germline DNA. Four coding SNP were identified. Eleven
informative SNP were genotyped in 159 HPC probands,
245 sporadic prostate cancer cases, and 222 unaffected
controls. Four of these SNP were statistically significant
for association with prostate cancer (P < 0.04), supporting
a role of LZTS1 in prostate cancer risk [11].
Effect of LZTS1 Gene Introduction Into Cancer Cells
Experimental studies using different cancer derived cell
lines from human bladder, breast and prostate tumor,
showed that reintroduction of LZTS1 results in inhibition
of tumor cell growth in vitro and/or tumorigenicity in
vivo.
In one study, introduction of full-length LZTS1 cDNA
resulted in suppression of tumorigenicity in nude mice, in
the inhibition of stable colony-forming efficiencies of
~50% of highly metastatic rat prostate cells and human
prostate and embryonic kidney cells, and in the reduction
of cell growth with accumulation of cells at late S to G2/M
stage of cell cycle [12]. In our studies, using breast cancer
(MCF7) and urothelial cancer derived cell lines (SW780)
we observed inhibition of cancer cell growth in vitro and
reduced tumorigenicity in vivo. In these studies we
pointed out that LZTS1 inhibits cancer cell growth
through the regulation of mitosis, interacting with CDK1,
an important factor for G2/M transition of cell cycle
[13,6].
Lzts1 is a tumor suppressor in mammals
To investigate the function of LZTS1 we generated Lzts1
Knockout mice (Lzts1-/-) [14]. In animals at the age of 8–
24 months (average 16 months), pathological analysis
demonstrated in animals either heterozygous or knockout
the onset of spontaneous neoplasms. The neoplasms in
Lzts1-/- mice were breast tumors, hepatocellular carcino-
mas, lymphomas, soft tissue sarcomas, and lung adeno-
mas, a spectrum suggesting that Lzts1 absence affects
multiple cell types in vivo. In addition we used NMBA
treatment to determine whether Lzts1 modulates carcino-
gen-induced malignancy development. Six weeks after
NMBA administration all 20 Lzts1-/- mice (100%) and all
Table 1: 
TUMOR DELETION RESULTS AFFECTED EXONS PUTATIVE PROTEIN 
CODED IN-FRAME
Esophagus 156–1542 FS Exons 1,2,3 Leucine Zip(-)
Esophagus 558–1715 IF Exons 2,3 Leucine Zip(-)
Esophagus 558–1715 IF Exons 2,3 Leucine Zip(-)
Esophagus 558–1715 IF Exons 2,3 Leucine Zip(-)
Esophagus 156–1542 FS Exons 1,2,3 Leucine Zip(-)
1402–1578 IF Exon 3 Leucine Zip(+)
Prostate 1366–1641 IF Exon 3 Leucine Zip(+)
1402–1578 IF Exon 3 Leucine Zip(+)
ALL 1402–1578 IF Exon 3 Leucine Zip(+)
Melanoma 1417–1515 IF Exon 3 Leucine Zip(+)
1516–1584 IF Exon 3 Leucine Zip(+)
IF, in-frame; FS, frameshift; Leucine Zip(-), Lzts1 protein coded in-frame with Leucine zipper; Leucine Zip(+), Lzts1 protein without Leucine 
zipper. ALL (acute lymphoblastic leukemia)Page 3 of 5
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forestomach, whereas only 5 of 30 Lzts1+/+ mice (17%)
developed tumors (Lzts1+/+ vs. Lzts1-/-, P < 0.001; Lzts1+/+
vs. Lzts1+/-, P < 0.001).
Histological sections showed an array of lesions typically
seen in NMBA-treated animals, including hyperplasia,
focal hyperplastic lesions, papillomas and carcinomas.
Lzts1-/- and Lzts1+/- mice developed at high frequency inva-
sive carcinoma of the forestomach, while Lzts1+/+ mostly
showed thin and regular epithelia. All Lzts1+/- mice
retained the wild type allele that was negative for muta-
tions, a finding suggesting haploinsufficiency of Lzts1.
Lzts1: a novel regulator of the cell cycle
Biochemical investigation of the mouse Lzts1 gene using
fibroblasts derived from Lzts1wt and null embryos (MEF),
revealed that Lzts1 wt and null MEFs displayed a normal
progression along the different phases of the cell cycle but
showed a faster M phase progression associated to a lower
Cyclin B1/Cdk1 activity [14]. Using video time-lapse
microscopy, we were able to demonstrate that the faster M
progression of Lzts1-/- cells was due to the time they spent
in prophase. The faster mitotic exit together with the
lower Cdk1 activity resulted in an increase in the number
of mitosis containing lagging chromosome with an
increased hypertetraploid cell population [14]. The time
to complete mitosis represents the key for proper DNA
separation. Lzts1 absence decreases Cdk1 activity result-
ing in prompt mitotic exit accompanied by defects in
DNA segregation. The mechanism whereby Lzts1 absence
decreases Cdk1 activity was sought investigating the mol-
ecule responsible for Cdk1 activation: namely Cdc25C.
Cdc25s family of phosphatase serves as a key activator of
the Cdks/Cyclins [15]. The three mammals Cdc25 phos-
phatase (Cdc25A, B and C) are responsible for dephosho-
rylating Cdks/cyclins on pThr14 and/or pTyr15 residues.
This dephosphorylation triggers the final activation of
Cdks/cyclins activity during normal cell cycle progression.
Recently we discovered that mitotic Lzts1-/- MEFs showed
a higher Cdk1-pY15/Cdk1 ratio accompanied by lower
levels of endogenous Cdc25C that results in a lower asso-
ciation between endogenous Cdc25C and endogenous
Cdk1.
It has been proposed that in G2/M arrested cells, Cdc25C
may be efficiently ubiquitinated [16]. Therefore we tested
whether Lzts1 might be involved in Cdc25C ubiquitina-
tion and we found that Lzts1 expression protects Cdc25C
from proteosome degradation during M phase, thereby
regulating Cdk1 activity [14] (Fig. 2).
This findings are rather surprising and change the classical
view of M phase entrance and progression that implicates
a central role for the high Cdk1 activity necessary for the
proper execution of M phase [17-19].
It is possible that decreased Cdk1 activity by changes in its
inhibitory phosphorylation during G2 phase may result
in G2 block of the cell cycle, whereas decreasing Cdk1
activity in M phase before the establishment of the met-
aphase plate causes a faster prometaphase progression
and mitotic exit, as in Lzts1-/-cells. In turn this event would
lead to higher percentage of improper chromosome segre-
gation resulting in cell transformation.
One intriguing observation is that Lzts1 absence seems to
affects Cdc25C levels in mitotic MEFs but not in cells
returned in G1 after the completion of cell division [14].
Accordingly, endogenous Lzts1 and Cdc25C proteins
associated better during M phase than in proliferating
Progression through the different stages of mitosis in Lzts1+/+ and Lzt 1-/- cellsFigu  2
Progression through the different stages of mitosis in 
Lzts1+/+ and Lzts1-/- cells. During prophase the interaction 
between Lzts1 and Cdc25C allows high levels of Cdc25C 
expression and activity resulting in normal progression from 
prophase to metaphase. In Lzts1 deficient cell during 
prophase, Cdc25C is rapidly ubiquitinated and degraded thus 
determining a low activity of the cyclin B1/Cdk1 complex. As 
a consequence the cell progress faster through prophase and 
prometaphase and frequently undergo to chromosomes mis-
segregation. Yellow arrows indicate lagging chromosomes in 
Lzts1-/- cells.Page 4 of 5
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cells extracts [14]. These observations suggest that in
mitotic cells one or both proteins undergo to post-transla-
tional modifications or bind yet unidentified factors spe-
cifically expressed during M phase that could favor their
interaction.
Conclusion
Human tumor suppressors often function as negative reg-
ulator of the cell cycle. In fact their mutations can lead to
failure of cell cycle checkpoint controls resulting in the
accumulation of genetic changes contributing to a tumor
phenotype. Several tumor suppressors are known to mod-
ulate the activities of Cdk/cyclin complexes. We focus here
on a newly identified factor: Lzts1 which alterations lead
to premature mitotic exit that results in chromosomal
instability and aneuploidy. Being Lzts1 frequently down-
regulated in many human tumors further investigations
are needed in order to better understand its functions,
eventually uncovering new opportunities for approaching
cancer and other proliferation-related diseases.
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